CD8A and neoplasm: Most likely, cancer vaccines will have to be combined with approaches targeting the immune suppressive microenvironment to eliminate MDSC and T regs and other suppressive mechanisms, thereby allowing the effector functions of tumor-specific CD8+ T cells.